Abstract:Background:Poor outcomes have been widely reported for younger vs. older breast cancer patients, but whether this is due to age itself or the enrichment of aggressive clinical features remains controversial. We have evaluated the clinicopathologic characteristics and genomic profiles of real-world hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (MBC) patients to examine the determinants of outcome for younger vs. older patients in a single clinical subtype undergoing treatment in the same clinic. Patients and methods:This study included patients presenting at the Peking University Cancer Hospital with primary stage IV or first-line metastatic HR+/HER2- breast cancer who consented to an additional blood draw for genomic profiling prior to treatment. Plasma samples were analyzed with a targeted 152-gene NGS panel to assess somatic circulating tumor DNA (ctDNA) alterations. Genomic DNA (gDNA) extracted from peripheral blood mononuclear cells was analyzed for germline variants using a targeted 600-gene NGS panel. Kaplan-Meier survival analysis was performed to analyze disease free survival (DFS), progression free survival (PFS) and overall survival (OS) in association with clinicopathologic and genomic variables. Results:Sixty-three patients presenting with HR+/HER2- MBC were enrolled in this study. Fourteen patients were < 40 years, 19 were 40-50 years, and 30 were > 50 years at the time of primary cancer diagnosis. No significant associations were observed between age and DFS, PFS or OS. Shorter OS was associated with de novo Stage IV disease (p = 0.002), Luminal B subtype (p = 0.006), high Ki67 index (p = 0.036), resistance to adjuvant endocrine therapy (p = 0.0001) and clinical stage (p = 0.015). Reduced OS was also observed in association with somatic alterations in FGFR1 (p = 0.008), CCND2 (p = 0.012), RB1 (p = 0.029) or TP53 (p = 0.029) genes, but not in association with germline variants. Conclusion:In this group of real-world HR+/HER2- MBC breast cancer patients younger age was not associated with poor outcomes. While current guidelines recommend treatment decisions based on tumor biology rather than age, young HR+ breast cancer patients are more likely to receive chemotherapy. Our findings support the development of biomarker-driven treatment strategies for these patients.

Reproductive Factors, Steroid Receptor Status, and Tumour Markers of HER2-Positive Breast Cancer in Northern China

The Impact of Reproductive Factors on the Risk of Breast Cancer by ER/PR and HER2: A Multicenter Case-Control Study in Northern and Eastern China

Association Between Hormone Receptors And Her-2/Neu Is Age-Related

The Diverse Distribution Of Risk Factors Between Breast Cancer Subtypes Of Er, Pr And Her2: A 10-Year Retrospective Multi-Center Study In China

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers

Reproductive factors and hormone receptor status among very young (<35 years) breast cancer patients

Clinical Pathologic Status and Expression of Tumor Markers in 5,000 Chinese Breast Cancers

A Clinical Database of Breast Cancer Patients Reveals Distinctive Clinico-Pathological Characteristics: a Study from Central China.

Attributable Causes of Breast Cancer and Ovarian Cancer in China: Reproductive Factors, Oral Contraceptives and Hormone Replacement Therapy

Clinical and Epidemiologic Factors Associated with Breast Cancer and Its Subtypes among Northeast Chinese Women

Risk Factors For Breast Cancer In Women Residing In Urban And Rural Areas Of Eastern China

The Prevalence and Correlates of Breast Cancer among Women in Eastern China

Comparison of Clinicopathological Features and Treatments between Young (≤40 Years) and Older (>40 Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter, Case Only Study.

The changes in female physical and childbearing characteristics in china and potential association with risk of breast cancer

Risk Factors Related to Female Breast Cancer in Regions of Northeast China: A 1:3 Matched Case-Control Population-Based Study

Epidemiology Of Triple Negative Breast Cancer In China

Association of Hormone-Related Characteristics and Breast Cancer Risk by Estrogen Receptor/progesterone Receptor Status in the Shanghai Breast Cancer Study.

Clinicopathologic Features, Genomic Profiles and Outcomes of Younger Vs. Older Chinese Hormone Receptor-Positive (Hr+)/her2-Negative (HER2-) Metastatic Breast Cancer Patients.

Socio-economic Factors Influencing Tumor Presentation and Treatment Options in Chinese Breast Cancer Patients

Clinicopathologic Characteristics and Prognosis in Young Chinese Women with Breast Cancer

Plasma Sex Steroid Hormones and Breast Cancer Risk in Chinese Women